Physician profile
Robert Powers
NPI 1417535949
$368.38
in general payments reported to CMS, 2019-2025
8 companies · $279 in 2025
The $279 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $89.46 · 2025: $279.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $368.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $368.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $189.46 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $51.93 | 2025 | |
| Amgen INC. | $47.35 | 2024 | Repatha, Otezla, Prolia |
| Exact Sciences Corporation | $21.14 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.86 | 2025 | Trelegy Ellipta |
| Lilly USA, LLC | $15.01 | 2024 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.03 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.60 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.